Utama › Kanser Serviks › Virginia › Arlington
Kajian klinikal Kanser Serviks di Arlington, VA
16 kajian untuk Kanser Serviks sedang mencari peserta di lokasi dalam dan sekitar Arlington (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Mengambil pesertaFasa 3
- Inova Schar Cancer Institute ( Site 5045), Fairfax · 11 mi jauh
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Mengambil pesertaFasa 1
- Virginia Cancer Specialists, Fairfax · 11 mi jauh
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Mengambil pesertaFasa 1/2
- NEXT Oncology, Fairfax · 11 mi jauh
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Mengambil pesertaFasa 1
- Virginia Cancer Specialists, Fairfax · 11 mi jauh
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Mengambil pesertaFasa 1
- NEXT Virginia, Fairfax · 11 mi jauh
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Mengambil pesertaFasa 1
- Normunity Investigational Site, Fairfax · 11 mi jauh
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Clinical Trial Site, Fairfax · 11 mi jauh
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Mengambil pesertaFasa 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi jauh
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Mengambil peserta
- Inova Health System, Fairfax · 11 mi jauh
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Mengambil pesertaFasa 1
- NEXT Virginia, Fairfax · 11 mi jauh
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- USO-Virginia Cancer Specialists, PC, Fairfax · 11 mi jauh
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Virginia Cancer Specialists, Fairfax · 11 mi jauh
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- NEXT, Fairfax · 11 mi jauh
Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women
Mengambil peserta
- ISA Associates, Arlington
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Mengambil pesertaFasa 1
- Dren Investigational Site, Fairfax · 11 mi jauh
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Research Site 102, Fairfax · 11 mi jauh
- Research Site 112, Fairfax · 11 mi jauh
Kajian Kanser Serviks di bandar lain
- Houston, TX34 kajian
- Nashville, TN19 kajian
- New York City, NY19 kajian
- Boston, MA18 kajian
- Los Angeles, CA16 kajian
- San Antonio, TX14 kajian
- St. Louis, MO13 kajian
- Dallas, TX13 kajian
- Orlando, FL12 kajian
- Chicago, IL12 kajian
- Atlanta, GA11 kajian
- Columbus, OH11 kajian
Kajian lain di Arlington
- Kanser Paru-paru Bukan Sel Kecil104 kajian
- Kanser Metastatik53 kajian
- Kanser Kolorektal52 kajian
- Kanser (semua jenis)48 kajian
- Kanser Payudara46 kajian
- Kanser Ovari46 kajian
- Kanser Paru-paru41 kajian
- Kanser Endometrium39 kajian
- Kanser Pankreas33 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher26 kajian
- Kanser Paru-paru Sel Kecil23 kajian
- Kanser Payudara Triple-Negatif20 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.